Emory’s minimally invasive approach is setting a new standard.
Since 2007, the Emory Structural Heart & Valve program has been pioneering a less invasive treatment for severe aortic stenosis, known as Transcatheter Aortic Valve Replacement (TAVR). Originally used to treat only those patients who were deemed a high-risk for traditional, surgical aortic valve replacement, TAVR has proven to be an effective treatment for intermediate-risk patients and is in trial with low-risk patients. Emory has performed over 5,000 TAVR procedures with excellent outcomes, continuing to lead the way in innovative, minimally-invasive procedures for patients.
